SYDNEY, Aug. 19, 2014 /PRNewswire/ -- Prima BioMed
Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", the
"Company") today announced that the abstract entitled, "Trial
evaluating overall survival in epithelial ovarian cancer (EOC)
patients in second remission with an autologous dendritic cell
therapy targeting mucin 1" has been accepted for a poster
presentation at the Society for Immunotherapy of Cancer ("SITC")
29th Annual Meeting.
The poster will be presented by Prima's Chief Technical Officer,
Dr. Sharron Gargosky, at the Gaylord
National Hotel and Convention Center in National Harbor, MD. Poster
presentations are scheduled to occur on Friday, November 7, 2014 and on Saturday, November 8, 2014 from 12:30 p.m. – 2:00
p.m. The exact time and location of Dr. Gargosky's poster
presentation will be available closer to the conference date.
About Prima BioMed
Prima BioMed is a globally active leader in cancer
immunotherapy. Prima is dedicated to leveraging its technology and
expertise to bring innovative treatment options to market for
patients and to maximize value to shareholders. Prima's lead
product is CVac™, an autologous dendritic cell-based product
currently in clinical trials. www.primabiomed.com.au
For further information please contact:
USA Investor/Media:
Adam Holdsworth, ProActive
Capital
+1 (646) 862 4607; adamh@proactivecapital.com
Australia Investor/Media:
Mr Matthew Gregorowski, Citadel
Communications
+61 (0) 422 534 755; mgregorowski@citadelpr.com.au
Europe Investor/Media:
Mr. Axel Muhlhaus, Edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de
SOURCE Prima BioMed